Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | VNN1 | O95497 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929610 | 0.83 | VNN1 (0.57) | DDR1CES2VNN1RAB9AALDH1A1 | |
| SCHEMBL6970291 | 0.83 | CES2 (0.61) | DDR1CES2ALDH1A1CTNNB1WNT3A | |
| SCHEMBL4313456 | 0.82 | LOXL2 (0.47) | RAB9AALDH1A1SMN1; SMN2CTNNB1WNT3A | |
| SCHEMBL3891876 | 0.81 | VNN1 (0.43) | VNN1SMN1; SMN2NR3C2CTNNB1WNT3A | |
| SCHEMBL3896447 | 0.81 | ERCC5 (0.46) | VNN1ALDH1A1 | |
| SCHEMBL3282343 | 0.81 | CES2 (0.54) | DDR1CES2ALDH1A1SMN1; SMN2CTNNB1 | |
| Bromide SCHEMBL6992895 | 0.80 | ERCC5 (0.44) | VNN1ALDH1A1 | |
| SCHEMBL3891730 | 0.80 | LOXL2 (0.41) | CNR2 | |
| SCHEMBL17581950 | 0.79 | CES2 (0.56) | DDR1CES2ALDH1A1CTNNB1WNT3A | |
| SCHEMBL7559508 | 0.79 | CES2 (0.70) | CES2CNR2TLR7ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854870-B1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-1109803-B1 | SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1414443-B1 | BENZIMIDAZO 4,5-f|ISOQUINOLINONE DERIVATIVES | MERCK & CO INC (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1414443-A4 | BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES | MERCK & CO INC (US) | 2005-05-11 | — | — | EP | disclosed |
| US-6852727-B2 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK & CO., INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK SHARP & DOHME LLC | 2004-09-09 | — | — | US | disclosed |
| US-6767908-B2 | TREATMENT OF CYTOKINE MEDIATED DISEASES SUCH AS ARTHRITIS. | MERCK & CO., INC | 2004-07-27 | — | — | US | disclosed |
| EP-1414443-A1 | BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES | Merck & Co., Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003011285-A1 | BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-1109803-A4 | SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 2002-10-29 | — | — | EP | disclosed |
| WO-2001057018-A1 | AZAAZULENE INHIBITORS OF P38 MAP KINASE AND TNF-ALPHA | ABBOTT LABORATORIES (US) | 2001-08-09 | — | — | WO | disclosed |
| EP-1109803-A1 | SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| US-6207687-B1 | USEFUL FOR TREATMENT OF CYTOKINE MEDIATED DISEASES SUCH AS ARTHRITIS | MERCK & CO., INC. | 2001-03-27 | — | — | US | disclosed |
| US-6083949-A | FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR | MERCK & CO., INC. (US) | 2000-07-04 | — | — | US | disclosed |
| WO-2000006563-A1 | SUBSTITUTED IMIDAZOLES HAVING CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0854870-A4 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | disclosed |
| EP-0854870-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | Merck & Co., Inc. (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5717100-A | Substituted imidazoles having anti-cancer and cytokine inhibitory activity | MERCK & CO., INC. (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1997012876-A9 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | — | 1997-09-18 | — | — | WO | disclosed |
| WO-1997012876-A1 | SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY | MERCK & CO., INC. (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | JAK1, JAK3, JAK2 | DDR1 3334/4885CES2 4828/4885VNN1 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.